You are here

Syndax Pharma

Ash 2021 preview – small increases and big falls

EP Vantage

Mon, 11/8/21 - 10:50 am

Global Blood Therapeutics

IGM Biosciences

Incyte and Syndax to jointly develop and commercialize axatilimab

Pharmaceutical Business Review

Tue, 09/28/21 - 12:01 pm

graft vs host disease

AskBio, Syndax and Catalyst All on the Fast Track

BioSpace

Mon, 06/28/21 - 06:56 pm

fast track status

Catalyst Biosciences

episodic bleeding

Syndax looks to rebound from stinging late-stage failure, uncorking early data for next cancer drug up

Endpoints

Tue, 04/20/21 - 07:35 pm

clinical trials

Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study

Endpoints

Fri, 05/18/18 - 12:17 pm

HDAC inhibitors

Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

Endpoints

Thu, 05/18/17 - 12:02 am

clinical trials

non-small cell lung cancer

Biotechs launch an IPO blitz as Nasdaq stumbles out of the gate

Fierce Biotech

Tue, 01/5/16 - 09:44 am

Editas Medicine

Audentes Therapeutics

Bavarian Nordic

Corvus Pharmaceuticals

Reata Pharmaceuticals

Syndax banks an $80M crossover round for PhIII cancer drug

Fierce Biotech

Mon, 08/24/15 - 11:32 am

Merck ties up with tiny Syndax on a 'breakthrough' cancer combo

Fierce Biotech

Tue, 03/31/15 - 12:40 pm

Syndax sets terms for a $69M IPO to support its 'breakthrough' drug

Fierce Biotech

Thu, 06/5/14 - 12:17 pm

breakthrough therapies

Syndax Pockets $26.6M For Final Stage Push With Cancer Drug

Xconomy

Tue, 08/27/13 - 09:57 am

Syndax Pharma, Ventana Medical enter pact to develop companion diagnostic test for entinostat

Pharmabiz

Sat, 01/7/12 - 02:30 pm

Ventana Medical Systems